TABLE 2.
Effects of dominant-negative STAT3 expression on cell cycle arrest of MTC cells upon LIF treatment or Raf activation
| Cell type | Infection | Treatment
|
% of cells in phase
|
|||
|---|---|---|---|---|---|---|
| LIF | Estradiol | G0/G1 | S | G2/M | ||
| TT | Control | − | 80.4 ± 0.40 | 13.0 ± 0.56 | 6.54 ± 0.15 | |
| + | 89.0 ± 0.52 | 7.01 ± 0.10 | 4.00 ± 0.41 | |||
| STAT3DNb | − | 81.8 ± 0.07 | 12.0 ± 0.06 | 6.14 ± 0.01 | ||
| + | 84.0 ± 0.75 | 11.1 ± 0.62c | 4.87 ± 0.13 | |||
| TTRaf | Control | − | 79.6 ± 0.03 | 15.7 ± 0.13 | 4.74 ± 0.15 | |
| + | 85.7 ± 0.96 | 6.70 ± 0.19 | 7.60 ± 1.09 | |||
| STAT3DN | − | 80.0 ± 1.06 | 14.9 ± 0.58 | 5.01 ± 0.48 | ||
| + | 88.5 ± 0.02 | 5.09 ± 0.31 | 6.46 ± 0.32 | |||
a
TT or TTRaf cells infected with AdSTAT3-DN were treated for 2 days with LIF or estradiol. Cells were also infected with the control AdGFP for comparison. Data (means ± standard errors) are from a representative experiment performed in triplicate. Experiments were repeated at least three times with similar results.
b
STAT3 DN, dominant-negative STAT3.
c
P < 0.02 compared to TT-control-LIF (one-way analysis of variance).